Celanese Corp

CE
About the company

Celanese Corporation produces and sells engineered polymers worldwide. It operates through Engineered Materials and Acetyl Chain segments.

Country: United StatesPrice: $51.41Market Cap: $5.6B

Investment snapshot

18%positive consensus
Scored 1d ago

Positive

3

BUY / PASS

Neutral / negative

3 / 10

NEUTRAL / FAIL

Median fair value

$94.80

+84.4% vs price

Models with upside

5 / 17

Positive margin of safety

Strongest signal

Models split on CE at $51.41 — fair values range $3.82–$398.05

Key risk

All 12 investors flag CE's debt & leverage

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #1259 (Top 40.7%)PASSFAILFAILNEUTRALFAILFAILPASSPASSNEUTRALFAILNEUTRALFAILFAIL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/A-1245.8%N/AN/A+58.4%N/A+87.1%+52.4%+15.2%+37.0%N/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-24

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-24

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-24

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-03

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-03

Score computed: 2026-11-14

Where It Passes

  • Valuation models83% pass✓ 5✗ 1▾

    Models split on CE at $51.41 — fair values range $3.82–$398.05

    Greenblatt fair value$3.82
    ✗Greenblatt-1245.8% margin vs $51.41
    Munger fair value$123.49
    ✓Munger+58.4% margin vs $51.41
    Akre fair value$398.05
    ✓Akre+87.1% margin vs $51.41
    Marks fair value$107.97
    ✓Marks+52.4% margin vs $51.41
    Ackman fair value$60.59
    ✓Ackman+15.2% margin vs $51.41
    Templeton fair value$81.63
    ✓Templeton+37.0% margin vs $51.41
  • Cash Flow80% pass✓ 10✗ 2▾

    8 of 10 pass — Buffett and Lynch object

    Free Cash Flow Proxy$-748.0M
    ✗BuffettPositive and growing
    FCF Positive and Growing$794.0M
    ✗LynchPositive and growing
    Operating Cash Flow$1.1B
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=5.28%, ROA=-5.37%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)4.9x
    ✓Dreman< 8x
    P/E or FCF YieldFCF Yield=14.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive20/21 years FCF positive
    ✓MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap14.1%
    ✓Ackman>= 4%
    Price / FCF per Share7.0x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency21/21 years positive
    ✓SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$794.0M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+14.07%; #451/4519 (top 10.0%)
    ✓OshaughnessyTop 10% of eligible cross-section

Where It Falls Short

  • Debt & Leverage0% pass✗ 15▾

    All 12 investors flag CE's debt & leverage

    LT Debt vs Net Current AssetsLT Debt $11.5B vs NCA $1.1B
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 2.74, IC: 1.1x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity2.74
    ✗Lynch< 0.33
    Cash - Long-term Debt$-10.2B
    ✗LynchPositive preferred
    LT Debt / Total Assets Change54.85% -> 58.14%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities1.26
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity2.74
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt Levels2.74
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=1.1x, D/EBITDA=7.1x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity2.74
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-2.7384; #3896/4210 (top 92.5%)
    ✗AsnessTop 30% of eligible cross-section
  • Efficiency0% pass✓ 1✗ 10▾

    No clean pass — all 8 investors flag at least one efficiency criterion

    Current Ratio1.26
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)5.1%
    ✗Buffett> 10%
    ROIC - WACC-4.9%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)17.4%
    ✗Greenblatt> 25%
    Current Ratio Change YoY1.32 -> 1.55
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.45x -> 0.44x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities1.26
    ✗Dreman> 1.5
    Return on Invested Capital3.9%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=6.3%; FY2024: ROIC=-3.2%; FY2025: ROIC=-3.7%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC3.7% (RR=95% x ROIC=3.9%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)1/5 years above 12% (latest -3.7%)
    ✗SleepROIC > 12% in a majority of years
  • Valuation15% pass✓ 9✗ 19▾

    11 of 13 flag CE's valuation — Graham, Lynch, Greenblatt +8 more

    Price / Book Value per Share1.4x
    ✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Net income / market capitalization+4.64%; #1795/6340 (top 28.3%)
    ✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio1.4x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value4.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=4.9%, ROC=17.4%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)4.9x
    ✓Dreman< 8x
    Valuation ReasonablenessOE Yield=-13.3%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=14.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=1.4x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share7.0x
    ✓Ackman<= 25
    Price vs. Trailing Low134% of trailing low ($38.44)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Positive book equity / market capitalization+0.7472; #2061/6449 (top 32.0%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+19.6%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+1.7455; #1198/5247 (top 22.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+14.07%; #451/4519 (top 10.0%)
    ✓OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-18.56%; #3892/6202 (top 62.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability19% pass✓ 9✗ 26▾

    13 of 16 flag CE's profitability — Graham, Buffett, Lynch +10 more

    Net income / market capitalization+4.64%; #1795/6340 (top 28.3%)
    ✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive EPS (10 years)18/26 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)23/26 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)9.5%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-8.2% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-748.0M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE6.2%
    ✗Lynch> 15%
    EBIT / Enterprise Value4.9%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=4.9%, ROC=17.4%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-5.37%
    ✗PiotroskiROA > 0
    ROA Change YoY-6.75% -> -5.37% (delta: +1.38%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=5.28%, ROA=-5.37%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY22.8% -> 20.5%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue3.4%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity6.2%
    ✗Dreman> 12%
    Margin of SafetyP/B=1.4x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-10.4% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency23/25 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue7.9%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity6.2%
    ✗Ackman>= 15%
    5-Year EPS CAGR2.3% CAGR over 3 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend15.2% (2023) -> -8.2% (2025)
    ✗TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 23.6% -> 20.5%, operating margin 15.2% -> -8.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Gross profit / total assets+9.78%; #2818/3702 (top 76.1%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity+6.21%; #2308/5226 (top 44.2%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0852; #3281/5884 (top 55.8%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR15.0% over 5 years
    ✓Neff7%-20% annualized
    Positive Diluted-EPS Years8/10 years positive
    ✓Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts21% pass✓ 3✗ 11▾

    Split decision: 10 FAIL · 3 PASS · 3 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (1/9)✗LynchFAIL (0/7)✗GreenblattRank #1259✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✗MungerFAIL (1/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (3/5)✓AckmanPASS (5/9)✓TempletonPASS (4/8)•SleepNEUTRAL (4/6)✗AsnessFAIL (Rank #1246/2370 (Top 52.6%))•NeffNEUTRAL (4/6)✗SchlossFAIL (3/7)✗OshaughnessyFAIL (Rank #696/963 (Top 72.3%))
  • Growth38% pass✓ 5✗ 8▾

    5 of 8 flag CE's growth — Graham, Lynch, Dreman +2 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 3.3% vs Rev: 1.4%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency23/25 years positive
    ✓MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-6.0%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency4/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR2.3% CAGR over 3 years
    ✓Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 23.6% -> 20.5%, operating margin 15.2% -> -8.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR11.0%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR15.0% over 5 years
    ✓Neff7%-20% annualized

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Chemicals
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($5.6B)
Revenue: $9.5B-7.1% YoY
Net Income: $1.2B+24.4% YoY

Financial Snapshot

Operating Margin-8.2%
Return on Equity-28.8%
Debt / Equity3.11
Current Ratio1.55
EPS (Diluted)$-10.64+3.3% 1y
Shares Retired−0.2% / −0.6% 2y

Similar Companies

CTA-PBEIDP, Inc.
$46.8B
CFCF Industries Holdings, Inc.
$18.3B
RPMRPM INTERNATIONAL INC/DE/
$13.2B
ESIElement Solutions Inc
$8.0B

Shareholder Return

Fiscal 2025

Issued 0.2% of shares last year, 0.6% issued over two.

Buybacks
—
Dividends
$13.0M

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY22
2.8% = 0.2% + 2.6%
FY23
3.3% = 2.6% + 0.7%
Earnings Fewer shares More shares

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, dividends paid.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, dividends paid.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, dividends paid.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-24
FY 2024
Sources
  • 10-K · 2025-02-21
FY 2023
Sources
  • 10-K · 2024-02-23
FY 2022
Sources
  • 10-K · 2023-02-24
FY 2021
Sources
  • 10-K · 2022-02-10
Market Cap$5.6Bcurrent------$4.9Best.$7.7Best.$15.6Best.$12.8Best.$15.7Best.
Revenue$9.8B↑1%$2.6B↑6%$2.8B↑9%$2.3B↓2%$9.5B↓7%$10.3B↓6%$10.9B↑13%$9.7B↑13%$8.5B
Operating Income$781.0M↑134%$198.0M↑116%$276.0M↑18%$214.0M↑27%-$786.0M↓9%-$720.0M↓143%$1.7B↑21%$1.4B↓29%$1.9B
Net Income$262.0M↑108%$74.0M↑105%$125.0M↓37%$44.0M↑310%-$1.2B↑24%-$1.5B↓179%$1.9B↑3%$1.9B$1.9B
EPS (Diluted)--$0.67↑105%$1.13↓38%$0.40↑311%$-10.64↑24%$-13.93↓178%$17.92↑3%$17.34↑3%$16.86
Gross Margin20.8%↓3%21.1%↓2%22.5%↑6%20.0%↑1%20.5%↓10%22.8%↓4%23.6%↓4%24.6%↓22%31.4%
Operating Margin7.9%↑134%7.7%↑115%10.0%↑9%9.2%↑30%-8.2%↓17%-7.0%↓146%15.2%↑7%14.2%↓38%22.8%
ROE6.2%↑108%———-28.8%↑4%-30.1%↓209%27.5%↓18%33.6%↓26%45.1%
Total Debt$11.5B↓10%$11.5B↓10%$12.0B↓7%$12.6B↓2%$12.6B$12.6B↓8%$13.7B↓7%$14.7B↑270%$4.0B
Shareholders' Equity$4.2B↑7%$4.2B↑7%$4.2B↓21%$4.1B↓22%$4.0B↓21%$5.1B↓27%$7.1B↑25%$5.6B↑35%$4.2B
Current Ratio1.26↓23%1.26↓23%1.45↓29%1.38↓29%1.55↑17%1.32↓14%1.53↓6%1.63↑7%1.52
Debt / Equity2.74↓16%2.74↓16%2.88↑17%3.09↑25%3.11↑27%2.45↑27%1.94↓26%2.60↑175%0.95
Operating Cash Flow$1.1B↓23%$538.0M↑20%$209.0M↓49%$76.0M↑105%$1.1B↑19%$966.0M↓49%$1.9B↑4%$1.8B↑4%$1.8B
Free Cash Flow$794.0M↓22%$469.0M↑22%$147.0M↓54%$10.0M↑115%$803.0M↑51%$531.0M↓60%$1.3B↑4%$1.3B↓1%$1.3B

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Chemicals

CE vs Peers — Financial Grading

Revenue$9.5BTop 25%
Net Income$1.2BBottom 25%
ROE-28.8%Bottom 25%
D/E3.11Bottom 25%
Op. Margin-8.2%Bottom 25%
Curr. Ratio1.55Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
EIDP, Inc.CTA-PB$46.8B$54.21——————2/95/92/70/3F-Score 14/11
CF Industries Holdings, Inc.CF$18.3B$125.09$7.1B$1.8B37.2%0.6632.5%3.373/94/95/73/3F-Score 88/11
RPM INTERNATIONAL INC/DE/RPM$13.2B$103.73$7.9B$661.4M20.0%0.77—1.683/92/93/71/3F-Score 67/11
Element Solutions IncESI$8.0B$33.08$2.6B$190.8M7.1%0.6113.4%3.682/92/91/71/3F-Score 56/11
NEWMARKET CORPNEU$6.5B$709.19$2.7B$418.7M23.5%0.5020.0%2.534/96/92/71/3F-Score 55/11
HEXCEL CORP /DE/HXL$6.0B$79.46$1.9B$109.4M8.7%0.799.1%2.262/92/93/70/3F-Score 64/11
ICL Group Ltd.ICL$5.8B$4.52$7.2B$226.0M3.8%0.468.1%1.335/94/92/70/3F-Score 45/11
BALCHEM CORPBCPC$5.5B$173.14$1.0B$154.8M12.3%0.1320.2%2.072/94/92/71/3F-Score 95/11